Progression of Prostate Cancer Despite an Extremely Low Serum Level of Prostate-Specific Antigen
Authors:
Open Access
- 1 January 2010
- journal article
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 51 (5) , 358-361
Abstract
A 61-year-old man who had been diagnosed with prostate cancer 9 years ago and had been treated with pelvic irradiation and intermittent androgen deprivation therapy visited the emergency room because of back pain and weakness in both legs. Spine magnetic resonance imaging showed a lumbar epidural mass and spine metastasis. The whole-body workup revealed multiple metastases to the lymph nodes, bone, liver, and lung. The serum prostate-specific antigen was 0.02 ng/ml. He underwent laminectomy, posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from the prostate was diagnosed. The patient underwent 1 cycle of docetaxel-based chemotherapy. More chemotherapy could not be done because of his general weakness. The patient died one month later of multiple organ failure.Keywords
This publication has 8 references indexed in Scilit:
- Hormonal therapyInternational Journal of Clinical Oncology, 2007
- Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen levelCancer, 2007
- Metastatic prostate cancer with normal level of serum prostate-specific antigenInternational Urology and Nephrology, 2003
- M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mLInternational Journal of Urology, 2001
- Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissueUrology, 2000
- Low PSA Metastatic Androgen– Independent Prostate CancerEuropean Urology, 2000
- The Incidence of Prostate Cancer Progression with Undetectable Serum Prostate Specific Antigen in a Series of 394 Radical ProstatectomiesJournal of Urology, 1995
- The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.1995